DrugsHumansHistone Deacetylase InhibitorsLymphomaLarge B-CellDiffuse
Ifupinostat: First Approval.
Simon Fung
Published: 202510.1007/s40265-025-02248-z
Abstract
Ifupinostat (; Betlin) is a first-in-class dual phosphoinositide 3-kinase α (PI3Kα)/histone deacetylase (HDAC) inhibitor being developed by BeBetter Med for the treatment of relapsed or refractory diffuse large B-cell lymphoma. On the 30th June 2025,…
Preview only. Read the full abstract at the source